Metabolomic Insights: Interplay Between Metabolism and Immune Response in Cancer

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Cell Metabolism".

Deadline for manuscript submissions: 20 February 2026 | Viewed by 1004

Special Issue Editor


E-Mail Website
Guest Editor
Department of Medicine, Division of Hematology Oncology, University of Washington, Seattle, WA 98109-1023, USA
Interests: cancer; immunotherapy; cancer cachexia; metabolism; metabolites
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Understanding the interplay between metabolism and the immune response in cancer is crucial for developing effective therapeutic strategies. Metabolomics, which involves the comprehensive analysis of small molecules (metabolites) within biological systems, offers a holistic view of cellular metabolism and its regulation in the context of cancer and the immune system.

In cancer, dysregulated metabolism is a hallmark feature, with altered nutrient uptake, energy production, and metabolite utilization, supporting tumor growth and progression. The immune system plays a pivotal role in cancer surveillance and defense, with immune cells capable of recognizing and eliminating cancerous cells. However, tumors often develop mechanisms to evade immune detection and suppress immune responses, creating an immunosuppressive microenvironment that facilitates tumor growth and metastasis. Metabolomic studies have uncovered intricate interactions between cancer metabolism and immune function, offering insights into the potential therapeutic targets and biomarkers.

The intention of this Special Issue is the enrichment and evolution of this research field pertaining to the interplay between metabolism and the immune response in cancer. We are pleased to invite clinicians and researchers to submit any relevant scientific work to this interesting and promising Special Issue of Metabolites.

We look forward to your contributions.

Dr. Dimitra Rafailia Bakaloudi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • metabolites
  • metabolism
  • cancer
  • immune response
  • immunotherapy
  • immunometabolism

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

9 pages, 874 KB  
Article
Paradoxical Regulation of α7nAChR and NLRP3 Inflammasome in Gastrointestinal Cancers and Ulcerative Colitis
by Gulten Ates, Ilker Ozgur and Ismail Cem Sormaz
Metabolites 2025, 15(9), 622; https://doi.org/10.3390/metabo15090622 - 18 Sep 2025
Viewed by 414
Abstract
Background: Gastrointestinal (GI) cancers are common and pose a major public health issue. An inflammatory microenvironment drives their development and progression. The α7nAChR receptor, known to suppress autoimmune and inflammatory bowel diseases, is also linked to colorectal cancer. It enhances anti-inflammatory activity, influences [...] Read more.
Background: Gastrointestinal (GI) cancers are common and pose a major public health issue. An inflammatory microenvironment drives their development and progression. The α7nAChR receptor, known to suppress autoimmune and inflammatory bowel diseases, is also linked to colorectal cancer. It enhances anti-inflammatory activity, influences tumor growth, metastasis, and treatment response, and is associated with tobacco use. NLRP3, a key inflammatory mediator, connects immunity and cancer. The α7nAChR receptor modulates tumorigenesis and therapy response by suppressing inflammatory pathways, while also regulating NLRP3 inflammasome activation through inhibition of mitochondrial DNA release. This study examines α7nAChR and NLRP3 expression in gastric and colorectal cancers, colitis, and normal tissues to clarify pathogenic mechanisms and identify therapeutic targets. Methods: Tissue samples of gastric tumor (S-Tm) (n = 10), colorectal tumor (C-Tm) (n = 10), colitis (UC) (n = 10), healthy stomach (S-C) (n = 10) and healthy colorectal tissue (C-C) (n = 10) taken during routine endoscopy protocols were homogenized. The α7nAChR and NLRP3 levels were examined using the ELISA method, and groups were compared. Results: We identified statistically significant differences in α7nAChR levels between the S-C and S-Tm (p < 0.05), C-C and C-Tm (p < 0.05), and S-C and C-Tm (p < 0.001) groups. The NRLP3 levels also differed significantly between the UC and C-Tm (p < 0.05), the S-C and C-Tm (p < 0.01), and the C-C and C-Tm groups (p < 0.01). Conclusions: Paradoxically, given the inflammatory regulatory role and oncogenic effects of α7nAChR, the relationship between α7nAChR and NLRP3 has become an important target for both oncological and inflammatory therapeutic approaches, particularly in inflammation-related GI cancers. Full article
Show Figures

Figure 1

Back to TopTop